{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:20:00Z","timestamp":1789014000468,"version":"build-2803163510"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200144"],"award-info":[{"award-number":["82200144"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100143"],"award-info":[{"award-number":["82100143"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key Research and Development Program of China","award":["2023YFC2507805"],"award-info":[{"award-number":["2023YFC2507805"]}]},{"name":"Wuhan Special Program for Knowledge Innovation","award":["2023020201010054"],"award-info":[{"award-number":["2023020201010054"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00277-025-06482-z","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:46:53Z","timestamp":1751359613000},"page":"3537-3551","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Immunotherapy-associated hemostatic abnormalities: bleeding and thrombotic complications"],"prefix":"10.1007","volume":"104","author":[{"given":"Yingying","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiwen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"11","key":"6482_CR1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ (2020) A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 20(11):651\u2013668","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"6482_CR2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41392-023-01521-5","volume":"8","author":"L Tang","year":"2023","unstructured":"Tang L, Huang Z, Mei H, Hu Y (2023) Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduct Target Therapy 8(1):306","journal-title":"Signal Transduct Target Therapy"},{"issue":"4","key":"6482_CR3","first-page":"233","volume":"5","author":"X Lyu","year":"2022","unstructured":"Lyu X, Zhao Q, Hui J et al (2022) The global landscape of approved antibody therapies. Antib Ther 5(4):233\u2013257","journal-title":"Antib Ther"},{"issue":"6","key":"6482_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.medj.2024.03.016","volume":"5","author":"J Shu","year":"2024","unstructured":"Shu J, Xie W, Chen Z et al (2024) The enchanting canvas of CAR technology: unveiling its wonders in non-neoplastic diseases. Med 5(6):495\u2013529","journal-title":"Med"},{"issue":"2","key":"6482_CR5","first-page":"86","volume":"70","author":"LB Kennedy","year":"2020","unstructured":"Kennedy LB, Salama AKS (2020) A review of cancer immunotherapy toxicity. CA Cancer J Clin 70(2):86\u2013104","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"6482_CR6","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA et al (2021) Society for immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 9(6):e002435","journal-title":"J Immunother Cancer"},{"issue":"4","key":"6482_CR7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","volume":"20","author":"JA Thompson","year":"2022","unstructured":"Thompson JA, Schneider BJ, Armand P et al (2022) Management of Immunotherapy-Related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20(4):387\u2013405","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"6482_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","volume":"14","author":"Z Tian","year":"2021","unstructured":"Tian Z, Liu M, Zhang Y, Wang X (2021) Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol Oncol 14(1):75","journal-title":"J Hematol Oncol"},{"issue":"25","key":"6482_CR9","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1182\/blood.2020009016","volume":"139","author":"MH Kroll","year":"2022","unstructured":"Kroll MH, Rojas-Hernandez C, Yee C (2022) Hematologic complications of immune checkpoint inhibitors. Blood 139(25):3594\u20133604","journal-title":"Blood"},{"issue":"4","key":"6482_CR10","first-page":"423","volume":"2","author":"J Roopkumar","year":"2021","unstructured":"Roopkumar J, Swaidani S, Kim AS et al (2021) Increased incidence of venous thromboembolism with Cancer immunotherapy. Med (N Y) 2(4):423\u2013434","journal-title":"Med (N Y)"},{"issue":"7","key":"6482_CR11","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00277-019-03685-z","volume":"98","author":"H Jiang","year":"2019","unstructured":"Jiang H, Liu L, Guo T et al (2019) Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy. Ann Hematol 98(7):1721\u20131732","journal-title":"Ann Hematol"},{"issue":"5","key":"6482_CR12","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/bjh.14680","volume":"181","author":"H Mei","year":"2018","unstructured":"Mei H, Jiang H, Wu Y et al (2018) Neurological toxicities and coagulation disorders in the cytokine release syndrome during CAR-T therapy. Br J Haematol 181(5):689\u2013692","journal-title":"Br J Haematol"},{"issue":"12","key":"6482_CR13","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1182\/blood.2020007878","volume":"137","author":"F Moik","year":"2021","unstructured":"Moik F, Chan W-SE, \u00a8uller SZo-M et al (2021) Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood 137(12):1669\u20131678","journal-title":"Blood"},{"issue":"26","key":"6482_CR14","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","volume":"121","author":"DT Teachey","year":"2013","unstructured":"Teachey DT, Rheingold SR, Maude SL et al (2013) Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121(26):5154\u20135157","journal-title":"Blood"},{"issue":"5","key":"6482_CR15","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","volume":"24","author":"EJ Davis","year":"2019","unstructured":"Davis EJ, Salem JE, Young A et al (2019) Hematologic complications of immune checkpoint inhibitors. Oncologist 24(5):584\u2013588","journal-title":"Oncologist"},{"issue":"14","key":"6482_CR16","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1097\/CM9.0000000000002288","volume":"135","author":"H Mei","year":"2022","unstructured":"Mei H, Chen F, Han Y et al (2022) Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy. Chin Med J (Engl) 135(14):1639\u20131641","journal-title":"Chin Med J (Engl)"},{"issue":"23","key":"6482_CR17","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM et al (2019) American society of hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3(23):3829\u20133866","journal-title":"Blood Adv"},{"key":"6482_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-017-0210-0","volume":"5","author":"E Shiuan","year":"2017","unstructured":"Shiuan E, Beckermann KE, Ozgun A et al (2017) Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J Immunother Cancer 5:8","journal-title":"J Immunother Cancer"},{"issue":"6","key":"6482_CR19","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.21037\/tlcr-21-464","volume":"10","author":"S Bai","year":"2021","unstructured":"Bai S, Tian T, Pacheco JM et al (2021) Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system. Transl Lung Cancer Res 10(6):2614\u20132624","journal-title":"Transl Lung Cancer Res"},{"key":"6482_CR20","doi-asserted-by":"publisher","first-page":"111606","DOI":"10.1016\/j.intimp.2024.111606","volume":"129","author":"DC Moore","year":"2024","unstructured":"Moore DC, Elmes JB, Arnall JR et al (2024) PD-1\/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review. Int Immunopharmacol 129:111606","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"6482_CR21","first-page":"13","volume":"45","author":"NR Wilson","year":"2022","unstructured":"Wilson NR, Lockhart JR, Garcia-Perdomo HA, Thein H, Oo aCMR, -H (2022) Management and outcomes of hematological Immune-related adverse events: systematic review and Meta-analysis. J Immunother Cancer 45(1):13\u201324","journal-title":"J Immunother Cancer"},{"key":"6482_CR22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","volume":"122","author":"JM Michot","year":"2019","unstructured":"Michot JM, Lazarovici J, Tieu A et al (2019) Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? Eur J Cancer 122:72\u201390","journal-title":"Eur J Cancer"},{"issue":"36","key":"6482_CR23","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of immune-Related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39(36):4073\u20134126","journal-title":"J Clin Oncol"},{"key":"6482_CR24","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3389\/fphar.2019.00454","volume":"10","author":"R Calvo","year":"2019","unstructured":"Calvo R (2019) Hematological side effects of immune checkpoint inhibitors: the example of immune-Related thrombocytopenia. Front Pharmacol 10:454","journal-title":"Front Pharmacol"},{"issue":"3","key":"6482_CR25","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/annonc\/mdv580","volume":"27","author":"S Kanameishi","year":"2016","unstructured":"Kanameishi S, Otsuka A, Nonomura Y et al (2016) Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells. Ann Oncol 27(3):546\u2013547","journal-title":"Ann Oncol"},{"issue":"5","key":"6482_CR26","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/bjh.15085","volume":"180","author":"T Kasamatsu","year":"2018","unstructured":"Kasamatsu T, Ino R, Takahashi N et al (2018) PDCD1 and CTLA4 polymorphisms affect the susceptibility to, and clinical features of, chronic immune thrombocytopenia. Br J Haematol 180(5):705\u2013714","journal-title":"Br J Haematol"},{"key":"6482_CR27","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.thromres.2020.09.038","volume":"196","author":"C Solinas","year":"2020","unstructured":"Solinas C, Saba L, Sganzerla P, Petrelli F (2020) Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review. Thromb Res 196:444\u2013453","journal-title":"Thromb Res"},{"issue":"1","key":"6482_CR28","doi-asserted-by":"publisher","first-page":"e001719","DOI":"10.1136\/jitc-2020-001719","volume":"9","author":"TA Sussman","year":"2021","unstructured":"Sussman TA, Li H, Hobbs B et al (2021) Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival. J Immunother Cancer 9(1):e001719","journal-title":"J Immunother Cancer"},{"issue":"18","key":"6482_CR29","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.3390\/cancers13184606","volume":"13","author":"TF Wang","year":"2021","unstructured":"Wang TF, Khorana AA, Carrier M (2021) Thrombotic complications associated with immune checkpoint inhibitors. Cancers (Basel) 13(18):4606","journal-title":"Cancers (Basel)"},{"key":"6482_CR30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejca.2021.09.010","volume":"158","author":"J Gong","year":"2021","unstructured":"Gong J, Drobni ZD, Alvi RM et al (2021) Immune checkpoint inhibitors for cancer and venous thromboembolic events. Eur J Cancer 158:99\u2013110","journal-title":"Eur J Cancer"},{"issue":"8","key":"6482_CR31","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.jsps.2022.06.010","volume":"30","author":"EA Alghamdi","year":"2022","unstructured":"Alghamdi EA, Aljohani H, Alghamdi W, Alharbi F (2022) Immune checkpoint inhibitors and potential risk of thromboembolic events: analysis of the WHO global database of individual case safety reports. Saudi Pharm J 30(8):1193\u20131199","journal-title":"Saudi Pharm J"},{"issue":"18","key":"6482_CR32","doi-asserted-by":"publisher","first-page":"18531","DOI":"10.1002\/cam4.6455","volume":"12","author":"J Zhu","year":"2023","unstructured":"Zhu J, Chen Y, Zhang Y et al (2023) Association of immune checkpoint inhibitors therapy with arterial thromboembolic events in cancer patients: A retrospective cohort study. Cancer Med 12(18):18531\u201318541","journal-title":"Cancer Med"},{"key":"6482_CR33","doi-asserted-by":"crossref","unstructured":"Song J, Morgan AA, Abram AMD et al (2025) Khorana risk score in lung cancer patients treated with immune checkpoint inhibitors: a real-world study. J Thromb Thrombolysis","DOI":"10.1007\/s11239-025-03086-2"},{"issue":"6","key":"6482_CR34","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3390\/jcm8060762","volume":"8","author":"R Sato","year":"2019","unstructured":"Sato R, Imamura K, Sakata S et al (2019) Disorder of Coagulation-Fibrinolysis system: an emerging toxicity of anti-PD-1\/PD-L1 monoclonal antibodies. J Clin Med 8(6):762","journal-title":"J Clin Med"},{"issue":"21","key":"6482_CR35","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.1182\/bloodadvances.2021004716","volume":"5","author":"A Johnsrud","year":"2021","unstructured":"Johnsrud A, Craig J, Baird J et al (2021) Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T cell therapy. Blood Adv 5(21):4465\u20134475","journal-title":"Blood Adv"},{"issue":"4","key":"6482_CR36","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1080\/10428194.2020.1852474","volume":"62","author":"AL Parks","year":"2021","unstructured":"Parks AL, Kambhampati S, Fakhri B et al (2021) Incidence, management and outcomes of arterial and venous thrombosis after chimeric antigen receptor modified T cells for B cell lymphoma and multiple myeloma. Leuk Lymphoma 62(4):1003\u20131006","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"6482_CR37","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.bbmt.2019.11.027","volume":"26","author":"Y Wang","year":"2020","unstructured":"Wang Y, Qi K, Cheng H et al (2020) Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 patients with relapsed and refractory hematologic malignancies. Biol Blood Marrow Transpl 26(5):865\u2013875","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"6482_CR38","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1038\/s41409-021-01226-9","volume":"56","author":"M Shao","year":"2021","unstructured":"Shao M, Yu Q, Teng X et al (2021) CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I\/II clinical trial. Bone Marrow Transpl 56(7):1642\u20131650","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"6482_CR39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","volume":"35","author":"A Passaro","year":"2024","unstructured":"Passaro A, Wang J, Wang Y et al (2024) Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol 35(1):77\u201390","journal-title":"Ann Oncol"},{"issue":"3","key":"6482_CR40","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jtha.2022.10.004","volume":"21","author":"M Shima","year":"2023","unstructured":"Shima M, Amano K, Ogawa Y et al (2023) A prospective, multicenter, open-label phase III study of Emicizumab prophylaxis in patients with acquired hemophilia A. J Thromb Haemost 21(3):534\u2013545","journal-title":"J Thromb Haemost"},{"issue":"2","key":"6482_CR41","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40265-018-0861-2","volume":"78","author":"LJ Scott","year":"2018","unstructured":"Scott LJ, Kim ES (2018) Emicizumab-kxwh: first global approval. Drugs 78(2):269\u2013274","journal-title":"Drugs"},{"issue":"1","key":"6482_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS et al (2015) Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 16(1):57\u201366","journal-title":"Lancet Oncol"},{"issue":"6","key":"6482_CR43","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.autrev.2017.04.012","volume":"16","author":"S Audia","year":"2017","unstructured":"Audia S, Mahevas M, Samson M et al (2017) Pathogenesis of immune thrombocytopenia. Autoimmun Rev 16(6):620\u2013632","journal-title":"Autoimmun Rev"},{"issue":"2","key":"6482_CR44","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/annonc\/mdx693","volume":"29","author":"L Leroy","year":"2018","unstructured":"Leroy L, Lafarge X, Blouin L et al (2018) A fatal allo- and immune-mediated thrombocytopenia with a PD-L1 inhibitor. Ann Oncol 29(2):514\u2013515","journal-title":"Ann Oncol"},{"key":"6482_CR45","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG (2021) Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol 16:223\u2013249","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"6482_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/imcb.1003","volume":"96","author":"V Sasidharan Nair","year":"2018","unstructured":"Sasidharan Nair V, Elkord E (2018) Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells. Immunol Cell Biol 96(1):21\u201333","journal-title":"Immunol Cell Biol"},{"key":"6482_CR47","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","volume":"322","author":"K Wing","year":"2008","unstructured":"Wing K, Onishi Y, Prieto-Martin P et al (2008) CTLA-4 control over Foxp3\u2009+\u2009regulatory T cell function. Science 322:271\u2013275","journal-title":"Science"},{"key":"6482_CR48","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.thromres.2019.07.001","volume":"181","author":"L Cheng","year":"2019","unstructured":"Cheng L, Liu C, Li F et al (2019) The prediction value of Treg cell subtype alterations for glucocorticoid treatment in newly diagnosed primary immune thrombocytopenia patients. Thromb Res 181:10\u201316","journal-title":"Thromb Res"},{"issue":"5","key":"6482_CR49","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1055\/s-0039-1679909","volume":"119","author":"M Nie","year":"2019","unstructured":"Nie M, Liu Y, Li X-X et al (2019) PD-1\/PD-L pathway potentially involved in ITP Immunopathogenesis. Thromb Haemost 119(5):758\u2013765","journal-title":"Thromb Haemost"},{"issue":"2","key":"6482_CR50","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/ajh.10278","volume":"72","author":"M Pavkovic","year":"2003","unstructured":"Pavkovic M, Georgievski B, Cevreska L et al (2003) CTLA-4 exon 1 polymorphism in patients with autoimmune blood disorders. Am J Hematol 72(2):147\u2013149","journal-title":"Am J Hematol"},{"issue":"8","key":"6482_CR51","first-page":"617","volume":"41","author":"Thrombosis and Hemostasis Group CSoH, Chinese Medical Association","year":"2020","unstructured":"Thrombosis and Hemostasis Group CSoH, Chinese Medical Association (2020) Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia (version 2020). Chin J Hematol 41(8):617\u2013623","journal-title":"Chin J Hematol"},{"issue":"1","key":"6482_CR52","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1186\/s12877-023-04181-w","volume":"23","author":"X Zhang","year":"2023","unstructured":"Zhang X, Gao B-x, Guo C-y, Su T (2023) A 71-year-old male with a life-threatening recurrence of hemolytic anemia, thrombocytopenia, and acute kidney injury after pembrolizumab therapy: a case report. BMC Geriatr 23(1):478","journal-title":"BMC Geriatr"},{"issue":"12","key":"6482_CR53","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/onco.13553","volume":"25","author":"M Gergi","year":"2020","unstructured":"Gergi M, Landry KK, Ades S et al (2020) Nivolumab-Induced thrombotic thrombocytopenic Purpura in a patient with anal squamous cell carcinoma: A lesson on hematologic toxicity from immunotherapy. Oncologist 25(12):1009\u20131012","journal-title":"Oncologist"},{"issue":"12","key":"6482_CR54","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1016\/j.jtho.2018.06.024","volume":"13","author":"R Kato","year":"2018","unstructured":"Kato R, Hayashi H, Sano K et al (2018) Nivolumab-Induced hemophilia A presenting as gastric ulcer bleeding in a patient with NSCLC. J Thorac Oncol 13(12):e239\u2013e241","journal-title":"J Thorac Oncol"},{"issue":"8","key":"6482_CR55","doi-asserted-by":"publisher","first-page":"e617","DOI":"10.1016\/S2352-3026(24)00144-3","volume":"11","author":"B Fattizzo","year":"2024","unstructured":"Fattizzo B, Marchetti M, Michel M et al (2024) Diagnosis and management of Evans syndrome in adults: first consensus recommendations. Lancet Haematol 11(8):e617\u2013e628","journal-title":"Lancet Haematol"},{"issue":"3","key":"6482_CR56","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s12328-023-01767-0","volume":"16","author":"M Fukushima","year":"2023","unstructured":"Fukushima M, Tajima K, Sasaki R et al (2023) Evans\u2019 syndrome induced by Atezolizumab plus bevacizumab combination therapy in advanced hepatocellular carcinoma. Clin J Gastroenterol 16(3):402\u2013406","journal-title":"Clin J Gastroenterol"},{"key":"6482_CR57","doi-asserted-by":"publisher","first-page":"109015","DOI":"10.1016\/j.intimp.2022.109015","volume":"110","author":"DC Moore","year":"2022","unstructured":"Moore DC, Elmes JB, Arnall JR et al (2022) Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system. Int Immunopharmacol 110:109015","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"6482_CR58","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1111\/hae.14632","volume":"28","author":"DC Moore","year":"2022","unstructured":"Moore DC, Elmes JB, Arnall JR et al (2022) Immune checkpoint inhibitor-induced acquired haemophilia: A pharmacovigilance analysis of the FDA adverse event reporting system. Haemophilia 28(5):e145\u2013e148","journal-title":"Haemophilia"},{"issue":"7","key":"6482_CR59","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/MBC.0000000000001244","volume":"34","author":"WJ Archibald","year":"2023","unstructured":"Archibald WJ, Kouides PA, Refaai MA, Lachant NA (2023) Acquired bleeding disorders secondary to immune checkpoint inhibitors: a case report and systematic literature review. Blood Coagul Fibrinolysis 34(7):427\u2013431","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"14","key":"6482_CR60","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1182\/blood.2020007338","volume":"137","author":"FI Mulder","year":"2021","unstructured":"Mulder FI, Horv\u00e1th-Puh\u00f3 E, Es N et al (2021) Venous thromboembolism in cancer patients: a population-based cohort study. Blood 137(14):1959\u20131969","journal-title":"Blood"},{"issue":"1","key":"6482_CR61","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/cancers12010067","volume":"12","author":"F Nichetti","year":"2019","unstructured":"Nichetti F, Ligorio F, Zattarin E et al (2019) Is there an interplay between immune checkpoint inhibitors, thromboprophylactic treatments and thromboembolic events?? Mechanisms and impact in Non-Small cell lung Cancer patients. Cancers (Basel) 12(1):67","journal-title":"Cancers (Basel)"},{"key":"6482_CR62","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.thromres.2021.06.018","volume":"205","author":"X Desch\u00eanes-Simard","year":"2021","unstructured":"Desch\u00eanes-Simard X, Richard C, Galland L et al (2021) Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study. Thromb Res 205:29\u201339","journal-title":"Thromb Res"},{"issue":"1","key":"6482_CR63","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1182\/blood-2022-160087","volume":"140","author":"F Moik","year":"2022","unstructured":"Moik F, Riedl J, Barth D et al (2022) Early dynamics of c-reactive protein predict risk of venous thromboembolism in patients with cancer treated with immune checkpoint inhibitors. Blood 140(1):1250\u20131251","journal-title":"Blood"},{"issue":"2","key":"6482_CR64","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/jth.13911","volume":"16","author":"T Iba","year":"2018","unstructured":"Iba T, Levy JH (2018) Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J Thromb Haemost 16(2):231\u2013241","journal-title":"J Thromb Haemost"},{"issue":"15","key":"6482_CR65","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-2463","volume":"22","author":"C Alfaro","year":"2016","unstructured":"Alfaro C, Teijeira A, O\u00f1ate C et al (2016) Tumor-Produced Interleukin-8 attracts human Myeloid-Derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs). Clin Cancer Res 22(15):3924\u20133936","journal-title":"Clin Cancer Res"},{"issue":"2","key":"6482_CR66","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1016\/S0049-3848(14)50007-2","volume":"133","author":"O K\u00f6nigsbr\u00fcgge","year":"2014","unstructured":"K\u00f6nigsbr\u00fcgge O, Pabinger I, Ay C (2014) Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and thrombosis study (CATS). Thromb Res 133(2):S39\u201343","journal-title":"Thromb Res"},{"issue":"10","key":"6482_CR67","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","volume":"122","author":"JF Timp","year":"2013","unstructured":"Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC (2013) Epidemiology of cancer-associated venous thrombosis. Blood 122(10):1712\u20131723","journal-title":"Blood"},{"issue":"5","key":"6482_CR68","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","volume":"38","author":"NS Key","year":"2020","unstructured":"Key NS, Khorana AA, Kuderer NM et al (2020) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 38(5):496\u2013520","journal-title":"J Clin Oncol"},{"issue":"12","key":"6482_CR69","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1111\/jth.15883","volume":"20","author":"TF Overvad","year":"2022","unstructured":"Overvad TF, Skjoth F, Piazza G et al (2022) The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: A Danish cohort study. J Thromb Haemost 20(12):2921\u20132929","journal-title":"J Thromb Haemost"},{"issue":"3","key":"6482_CR70","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.3390\/curroncol30030230","volume":"30","author":"T-F Wang","year":"2023","unstructured":"Wang T-F, Carrier M (2023) Immune checkpoint Inhibitors-Associated thrombosis: incidence, risk factors and management. Curr Oncol 30(3):3032\u20133046","journal-title":"Curr Oncol"},{"issue":"10","key":"6482_CR71","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1055\/s-0042-1749185","volume":"122","author":"Z Ma","year":"2022","unstructured":"Ma Z, Sun X, Zhang Y et al (2022) Risk of thromboembolic events in Cancer patients treated with immune checkpoint inhibitors: A Meta-analysis of randomized controlled trials. Thromb Haemost 122(10):1757\u20131766","journal-title":"Thromb Haemost"},{"key":"6482_CR72","doi-asserted-by":"publisher","first-page":"109243","DOI":"10.1016\/j.thromres.2024.109243","volume":"246","author":"J Lin","year":"2025","unstructured":"Lin J, Li W, Zhang X et al (2025) Thromboembolic events associated with immune checkpoint inhibitors in cancer patients: A bayesian network meta-analysis. Thromb Res 246:109243","journal-title":"Thromb Res"},{"issue":"7181","key":"6482_CR73","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nature06797","volume":"451","author":"N Mackman","year":"2008","unstructured":"Mackman N (2008) Triggers, targets and treatments for thrombosis. Nature 451(7181):914\u2013918","journal-title":"Nature"},{"issue":"9","key":"6482_CR74","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.3390\/cells9091987","volume":"9","author":"K Poels","year":"2020","unstructured":"Poels K, van Leent MMT, Reiche ME et al (2020) Antibody-Mediated Inhibition of CTLA4 aggravates atherosclerotic plaque inflammation and progression in hyperlipidemic mice. Cells 9(9):1987","journal-title":"Cells"},{"issue":"24","key":"6482_CR75","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","volume":"142","author":"ZD Drobni","year":"2020","unstructured":"Drobni ZD, Alvi RM, Taron J et al (2020) Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation 142(24):2299\u20132311","journal-title":"Circulation"},{"issue":"5","key":"6482_CR76","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","volume":"31","author":"D-x Bu","year":"2011","unstructured":"Bu D-x, Tarrio M, Maganto-Garcia E et al (2011) Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler Thromb Vasc Biol 31(5):1100\u20131107","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"6482_CR77","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1172\/JCI31344","volume":"117","author":"I Gotsman","year":"2007","unstructured":"Gotsman I, Grabie N, Dacosta R et al (2007) Proatherogenic immune responses are regulated by the PD-1\/PD-L pathway in mice. J Clin Invest 117(10):2974\u20132982","journal-title":"J Clin Invest"},{"issue":"1","key":"6482_CR78","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00395-024-01068-8","volume":"120","author":"TG Gergely","year":"2025","unstructured":"Gergely TG, Drobni ZD, Sayour NV et al (2025) Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors. Basic Res Cardiol 120(1):187\u2013205","journal-title":"Basic Res Cardiol"},{"key":"6482_CR79","doi-asserted-by":"publisher","first-page":"101220","DOI":"10.1016\/j.blre.2024.101220","volume":"67","author":"J Chen","year":"2024","unstructured":"Chen J, Liu S, Ruan Z et al (2024) Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk. Blood Rev 67:101220","journal-title":"Blood Rev"},{"key":"6482_CR80","doi-asserted-by":"publisher","first-page":"16037","DOI":"10.1038\/nrdp.2016.37","volume":"2","author":"S Gando","year":"2016","unstructured":"Gando S, Levi M, Toh CH (2016) Disseminated intravascular coagulation. Nat Rev Dis Primers 2:16037","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"6482_CR81","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2217\/imt-2020-0018","volume":"12","author":"A Alberti","year":"2020","unstructured":"Alberti A, Mancin M, Cortinovis D et al (2020) Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab. Immunotherapy 12(9):629\u2013633","journal-title":"Immunotherapy"},{"issue":"1","key":"6482_CR82","doi-asserted-by":"publisher","first-page":"e818","DOI":"10.1097\/CAD.0000000000001230","volume":"33","author":"M Hashimoto","year":"2022","unstructured":"Hashimoto M, Nakayama T, Fujimoto S et al (2022) Disseminated intravascular coagulation induced by pazopanib following combination therapy of nivolumab plus ipilimumab in a patient with metastatic renal cell carcinoma. Anticancer Drugs 33(1):e818\u2013e821","journal-title":"Anticancer Drugs"},{"issue":"4","key":"6482_CR83","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1055\/s-0039-1687890","volume":"45","author":"M Levi","year":"2019","unstructured":"Levi M (2019) Disseminated intravascular coagulation in cancer: an update. Semin Thromb Hemost 45(4):342\u2013347","journal-title":"Semin Thromb Hemost"},{"issue":"19","key":"6482_CR84","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1056\/NEJMra0904569","volume":"364","author":"C Scott","year":"2011","unstructured":"Scott C, Howard MD, Deborah P, Jones MD, Pui C-H, M.D (2011) The tumor Lysis syndrome. N Engl J Med 364(19):1844\u20131854","journal-title":"N Engl J Med"},{"issue":"15","key":"6482_CR85","first-page":"1327","volume":"86","author":"FBT Toh Jr","year":"2001","unstructured":"Toh FBT Jr, Hoots C-H WK et al (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation - On behalf of the scientific subcommittee on disseminated intravascular coagulation (DIC) of the international society on thrombosis and haemostasis (ISTH). Thromb Haemost 86(15):1327\u20131330","journal-title":"Thromb Haemost"},{"key":"6482_CR86","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12959-016-0117-x","volume":"14","author":"H Asakura","year":"2016","unstructured":"Asakura H, Takahashi H, Uchiyama T et al (2016) DIC subcommittee of the Japanese society on thrombosis and hemostasis. Proposal for new diagnostic criteria for DIC from the Japanese society on thrombosis and hemostasis. Thromb J 14:42","journal-title":"Thromb J"},{"issue":"5","key":"6482_CR87","first-page":"361","volume":"38","author":"Thrombosis and Hemostasis Group HSoCMA","year":"2017","unstructured":"Thrombosis and Hemostasis Group HSoCMA (2017) Consensus of Chinese experts on diagnosis of disseminated intravascular coagulation (version 2017). Chin J Hematol 38(5):361\u2013363","journal-title":"Chin J Hematol"},{"issue":"6","key":"6482_CR88","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1111\/1346-8138.15336","volume":"47","author":"H Kuriyama","year":"2020","unstructured":"Kuriyama H, Fukushima S, Nakahara S et al (2020) Serious disseminated intravascular coagulation associated with combination therapy of nivolumab and ipilimumab in advanced melanoma. J Dermatol 47(6):e235\u2013e237","journal-title":"J Dermatol"},{"issue":"6","key":"6482_CR89","doi-asserted-by":"publisher","first-page":"e005898","DOI":"10.1136\/jitc-2022-005898","volume":"11","author":"J Jess","year":"2023","unstructured":"Jess J, Yates B, Dulau-Florea A et al (2023) CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity. J Immunother Cancer 11(6):e005898","journal-title":"J Immunother Cancer"},{"issue":"12","key":"6482_CR90","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1007\/s00277-023-05477-y","volume":"102","author":"X Wang","year":"2023","unstructured":"Wang X, Li C, Luo W et al (2023) IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapy. Ann Hematol 102(12):3575\u20133585","journal-title":"Ann Hematol"},{"issue":"17","key":"6482_CR91","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1182\/bloodadvances.2020002060","volume":"4","author":"H Hashmi","year":"2020","unstructured":"Hashmi H, Mirza AS, Darwin A et al (2020) Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. Blood Adv 4(17):4086\u20134090","journal-title":"Blood Adv"},{"issue":"2","key":"6482_CR92","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1182\/bloodadvances.2020002757","volume":"5","author":"J Buechner","year":"2021","unstructured":"Buechner J, Grupp SA, Hiramatsu H et al (2021) Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. Blood Adv 5(2):593\u2013601","journal-title":"Blood Adv"},{"issue":"9","key":"6482_CR93","doi-asserted-by":"publisher","first-page":"e414","DOI":"10.1016\/S2352-3026(17)30108-4","volume":"4","author":"T Luft","year":"2017","unstructured":"Luft T, Benner A, Jodele S et al (2017) EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. Lancet Haematol 4(9):e414\u2013e423","journal-title":"Lancet Haematol"},{"issue":"1","key":"6482_CR94","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/bjh.18596","volume":"201","author":"E Galli","year":"2022","unstructured":"Galli E, Sora F, Hohaus S et al (2022) Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells. Br J Haematol 201(1):86\u201394","journal-title":"Br J Haematol"},{"issue":"21","key":"6482_CR95","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D et al (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130(21):2295\u20132306","journal-title":"Blood"},{"issue":"4","key":"6482_CR96","doi-asserted-by":"publisher","first-page":"e006365","DOI":"10.1136\/jitc-2022-006365","volume":"11","author":"AB Moreno-Casta\u00f1o","year":"2023","unstructured":"Moreno-Casta\u00f1o AB, Fern\u00e1ndez S, Ventosa H et al (2023) Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis. J ImmunoTher Cancer 11(4):e006365","journal-title":"J ImmunoTher Cancer"},{"issue":"4","key":"6482_CR97","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl 25(4):625\u2013638","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"6482_CR98","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le RQ, Li L, Yuan W et al (2018) FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T Cell-Induced severe or Life-Threatening cytokine release syndrome. Oncologist 23(8):943\u2013947","journal-title":"Oncologist"},{"issue":"7","key":"6482_CR99","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN (2024) Current Understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol 21(7):501\u2013521","journal-title":"Nat Rev Clin Oncol"},{"key":"6482_CR100","doi-asserted-by":"publisher","first-page":"745320","DOI":"10.3389\/fimmu.2021.745320","volume":"12","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Pacheco Sanchez G, Sharma A et al (2021) Prophylactic Tocilizumab prior to Anti-CD19 CAR-T cell therapy for Non-Hodgkin lymphoma. Front Immunol 12:745320","journal-title":"Front Immunol"},{"issue":"6","key":"6482_CR101","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jtct.2021.03.004","volume":"27","author":"R Banerjee","year":"2021","unstructured":"Banerjee R, Marsal J, Huang CY et al (2021) Early Time-to-Tocilizumab after B cell maturation antigen-Directed chimeric antigen receptor T cell therapy in myeloma. Transpl Cell Ther 27(6):477","journal-title":"Transpl Cell Ther"},{"key":"6482_CR102","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","volume":"130","author":"FL Locke","year":"2017","unstructured":"Locke FL, Neelapu SS, Bartlett NL et al (2017) Preliminary results of prophylactic Tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory,aggressive Non-Hodgkin lymphoma (NHL). Blood 130:1547","journal-title":"Blood"},{"issue":"2 Suppl","key":"6482_CR103","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1097\/CCM.0b013e3181c98d21","volume":"38","author":"M Levi","year":"2010","unstructured":"Levi M, van der Poll T (2010) Inflammation and coagulation. Crit Care Med 38(2 Suppl):S26\u201334","journal-title":"Crit Care Med"},{"issue":"13","key":"6482_CR104","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1182\/blood-2018-08-868067","volume":"132","author":"SP Grover","year":"2018","unstructured":"Grover SP, Mackman N (2018) Neutrophils, nets, and immunothrombosis. Blood 132(13):1360\u20131361","journal-title":"Blood"},{"issue":"2","key":"6482_CR105","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41577-019-0215-7","volume":"20","author":"T Gong","year":"2020","unstructured":"Gong T, Liu L, Jiang W, Zhou R (2020) DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol 20(2):95\u2013112","journal-title":"Nat Rev Immunol"},{"issue":"25","key":"6482_CR106","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1182\/blood.2023021166","volume":"142","author":"J Yong","year":"2023","unstructured":"Yong J, Toh C-H (2023) Rethinking coagulation: from enzymatic cascade and cell-based reactions to a convergent model involving innate immune activation. Blood 142(25):2133\u20132145","journal-title":"Blood"},{"issue":"22","key":"6482_CR107","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1161\/01.CIR.0000131660.51520.9A","volume":"109","author":"M Levi","year":"2004","unstructured":"Levi M, van der Poll T, Buller HR (2004) Bidirectional relation between inflammation and coagulation. Circulation 109(22):2698\u20132704","journal-title":"Circulation"},{"issue":"3","key":"6482_CR108","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3390\/cancers12030546","volume":"12","author":"F Petrelli","year":"2020","unstructured":"Petrelli F, Signorelli D, Ghidini M et al (2020) Association of steroids use with survival in patients treated with immune checkpoint inhibitors: A systematic review and Meta-Analysis. Cancers (Basel) 12(3):546","journal-title":"Cancers (Basel)"},{"issue":"5","key":"6482_CR109","doi-asserted-by":"publisher","first-page":"e002535","DOI":"10.1136\/jitc-2021-002535","volume":"9","author":"AA Tarhini","year":"2021","unstructured":"Tarhini AA, Kang N, Lee SJ et al (2021) Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer 9(5):e002535","journal-title":"J Immunother Cancer"},{"issue":"21","key":"6482_CR110","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1097\/CM9.0000000000002544","volume":"136","author":"N Li","year":"2023","unstructured":"Li N, Zheng X, Gan J et al (2023) Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors. Chin Med J (Engl) 136(21):2562\u20132572","journal-title":"Chin Med J (Engl)"},{"key":"6482_CR111","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ejca.2020.12.012","volume":"145","author":"M Skribek","year":"2021","unstructured":"Skribek M, Rounis K, Afshar S et al (2021) Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. Eur J Cancer 145:245\u2013254","journal-title":"Eur J Cancer"},{"key":"6482_CR112","doi-asserted-by":"publisher","first-page":"114172","DOI":"10.1016\/j.ejca.2024.114172","volume":"207","author":"RJ Verheijden","year":"2024","unstructured":"Verheijden RJ, Burgers FH, Janssen JC et al (2024) Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma. Eur J Cancer 207:114172","journal-title":"Eur J Cancer"},{"issue":"6","key":"6482_CR113","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/2159-8290.CD-20-1209","volume":"11","author":"TA Yap","year":"2021","unstructured":"Yap TA, Parkes EE, Peng W et al (2021) Development of immunotherapy combination strategies in Cancer. Cancer Discov 11(6):1368\u20131397","journal-title":"Cancer Discov"},{"key":"6482_CR114","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.bbrc.2023.01.096","volume":"649","author":"HH Nguyen","year":"2023","unstructured":"Nguyen HH, Bui KC, Nguyen TML et al (2023) The safety of CAR-T cells and PD-1 antibody combination on an experimental model. Biochem Biophys Res Commun 649:25\u201331","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"6482_CR115","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli PS, Zauderer MG, Riviere I et al (2021) A phase I trial of regional Mesothelin-Targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the Anti-PD-1 agent pembrolizumab. Cancer Discov 11(11):2748\u20132763","journal-title":"Cancer Discov"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06482-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06482-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06482-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:39:40Z","timestamp":1757209180000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06482-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":115,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["6482"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06482-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"11 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}